v3.26.1
Business Segments (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
In addition to the significant expense categories included within the consolidated statements of loss and comprehensive loss, the following table sets forth disaggregated research and development expenses:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Zanidatamab$2,181 $1,501 $2,805 $2,905 
ZW171(458)3,322 691 5,549 
ZW1913,127 2,764 6,158 4,470 
ZW220(152)327 (55)2,525 
ZW2513,205 2,340 5,112 6,291 
Expense for other preclinical and research programs4,192 6,174 11,456 12,250 
Unallocated research and development expenses:
Salaries and benefits and stock based compensation
10,681 12,034 25,440 24,757 
Other research and development expense4,659 5,987 10,285 11,440 
Total research and development expenses
$27,435 $34,449 $61,892 $70,187